Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
-  Evaluation of the non inferiority of Meclin (meclizine) versus Dramin (Dimenhydrinate)
 to treat the symptoms of acute vertigo from peripheral origin after up to 4 weeks of
 treatment;

 -  Evaluation of impact on quality of life in vertigo;

 -  Compare the intensity of daytime sleepiness in the two treatment groups;

 -  Compare the efficacy of drugs in relieving each of the 10 symptoms that make up the VS;

 -  Compare the duration of treatment in both treatment groups;

 -  Compare Adehence;

 -  Compare the level of satisfaction from each group from the investigators and the
 subjects;

 -  Adverse events;
It is a prospective interventional study arms parallel , active -controlled , non-inferiority
 . Participants selected for the study should be of both sexes , aged over 18 years and less
 than 65, which meet all the inclusion criteria and did not fit any exclusion criteria , and
 agree to all the purposes of the study. Participants are divided into two according to the
 randomization treatment groups 1:1.

 The study should take no longer than 30 days to be completed with the amount of 6 visits (7±2
 days): V0 radomization; V1, V2, V3 andV4(FV) are Evaluation visits and One Follow up visit
 7±2 days after the Final Visit.
Inclusion Criteria:

 -  Men and women aged over 18 years and less than 65;

 -  Presence of vertigo episodes of vestibular origin (peripheral ) of moderate intensity
 , strong or very strong according to the VS range ;

 -  Participants who are able to swallow tablets / capsules;

 -  Participants able to understand the guidance and care of this study and cooperative ;

 -  Participants with the requisite understanding, in accordance with Good Clinical
 Practice Research Document of the Americas.

 Exclusion Criteria:

 -  Use of meclizine or dimenidrynate in the actual event or in the past 15 days;

 -  Use of alcohol in the past 48 hours;

 -  Presence of vomiting which prevent the ingestion of tablets;

 -  Pregnancy or breastfeeding;

 -  Presence of clinical condition that determines contraindication to the active
 substances : convulsions , suspected intracranial compressive processes , closed-angle
 glaucoma , prostatic adenoma with urinary disorders , liver diseases , endocrine ,
 renal, and / or uncontrolled cardiovascular , Parkinson's disease, porphyria, know
 history of hipersensibility to the Actives or Excipients from the study medications;

 -  Malignancies History , even if no evidence of active disease for less than five years
 . Those without active disease for more than five years may be included;

 -  Uncontrolled systemic arterial hypertension ( > 140/90 mmHg );

 -  Decompensated diabetes mellitus (blood glucose at any time > 200 mg / dL );

 -  Participants with asthma or chronic obstructive pulmonary disease;

 -  Participants making use of antihistamines with anti-vertigo effect ( betahistine,
 meclizine , diphenidol ) , drugs with antagonist calcium channel action ( cinnarizine
 , flunarizine ) , anticholinergic drugs ( metoclopramide , dimenhydrinate , meclizine
 , diphenidol , scopolamine, ondansetron, granisetron ) , antiseizure drugs ( diazepam
 , clonazepam , carbamazepine ) and other central nervous system depressants;

 -  Participants with central origin vertigo or non-vestibular;

 -  Participants with positional benign positional paroxysmal vertigo (bppv).